<DOC>
	<DOCNO>NCT00781612</DOCNO>
	<brief_summary>This global , multicenter , open-label extension study . Participants receive single-agent trastuzumab emtansine trastuzumab emtansine administer combination agent Genentech/Roche-sponsored study complete parent study continue receive study drug ( ) time parent study closure eligible continue treatment study .</brief_summary>
	<brief_title>A Safety Extension Study Trastuzumab Emtansine Participants Previously Treated With Trastuzumab Emtansine Alone Combination With Other Anti-Cancer Therapy One Parent Studies</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Completed singleagent trastuzumab emtansine combination trastuzumab emtansine treatment parent study continue receive singleagent trastuzumab emtansine combination trastuzumab emtansine treatment time parent study closure receive last study drug dose within 6 week ( 42 day ) prior first schedule dose study therapy extension study Continue receive treatment control arm study TDM4450g ( NCT00679341 ) time parent study closure participant receive last dose control arm study drug within 6 week ( 42 day ) prior first schedule dose control arm study therapy extension study Participants control arm Study TDM4450g whose disease progression ( PD ) occur transition interval parent study extension study may initiate trastuzumab emtansine treatment time enrollment study TDM4529g ( NCT00781612 ) Expectation investigator participant may continue benefit additional singleagent trastuzumab emtansine combination trastuzumab emtansine treatment Expectation investigator participant may continue benefit control arm treatment give study TDM4450g time disease progression may benefit singleagent trastuzumab emtansine treatment Women childbearing potential men partner childbearing potential , must willing use highly effective form nonhormonal contraception two effective form nonhormonal contraception participant and/or partner , continue use contraception duration study treatment least 7 month last dose study treatment Male participant whose partner pregnant use condom duration pregnancy AEs lead singleagent trastuzumab emtansine combination trastuzumab emtansine treatment discontinuation parent study Ongoing SAEs parent study Progressive disease singleagent trastuzumab emtansine trastuzumab emtansinecontaining regimen parent study start extension study , exception participant study TDM4688g ( NCT00943670 ) early PD go receive pertuzumab + trastuzumab emtansine treatment experience disease progression combination regimen Peripheral neuropathy Grade great equal ( &gt; /= ) 3 per National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) , Version 3.0 4.0 , utilized parent study History symptomatic congestive heart failure ( [ CHF ] ; New York Heart Association [ NYHA ] Classes IIIV ) , ventricular arrhythmia require treatment , current unstable angina , history myocardial infarction within 6 month prior study entry Severe dyspnea rest due complication advance malignancy current requirement continuous oxygen therapy Current severe , uncontrolled systemic disease ( e.g . clinically significant cardiovascular , pulmonary , metabolic disease ) Major surgical procedure significant traumatic injury within 28 day prior study entry anticipation need major surgery course study treatment Current pregnancy lactation History receive investigational treatment systemic therapy direct control cancer ( e.g. , chemotherapy , trastuzumab , etc . ) since participant 's last study drug dose parent study History hypersensitivity previous trastuzumab emtansine agent use trastuzumab emtansine parent study , preclude dose Assessed investigator unable unwilling comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>